Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
LUME study of nintedanib finds improved PFS, but no overall survival boost

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.10.16
Views: 1310
Rating:

Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium

Prof Van Cutsem speaks with ecancertv at ESMO 2016 about the LUME trial assessing response of patients with colon cancer to nintedanib.

He describes the study design, including the multiple targets of nintedanib, and the mixed outcomes of  improves PFS but no overall survival benefit.

News coverage of the study is available here.

Prof Van Cutsem also spoke with ecancer, here, about the impact of tumour location determined through the CRYSTAL trial.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation